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We enrolled 141 maternal health-
care providers from 49 countries 
in all six WHO regions; 105 (74%) 
respondents were from low-income 
and middle-income countries (LMICs). 
24 (17%) participants were recruited 
from the teaching programmes 
Eﬀ ect of package insert 
language on health-care 
providers’ perceptions 
of inﬂ uenza vaccination 
safety during pregnancy 
Despite national and international 
recommendations that support 
inﬂ uenza immunisation in pregnant 
women, global adoption of these 
programmes is inadequate.1 Reviews 
by public health experts of inactivated 
inﬂ uenza vaccines have not identiﬁ ed 
safety concerns in pregnant women 
or their offspring.2 These reviews 
were based largely on non-product-
speciﬁ c data and observational studies 
because data from product-specific, 
randomised controlled trials in 
pregnant women are scarce. However, 
clinical trial data are the basis for 
the language of the vaccine product 
information and package inserts 
approved by regulatory authorities 
regarding indications, safety, and use 
in speciﬁ c populations.3 Pregnancy is 
not a contraindication for use of most 
seasonal inactivated inﬂ uenza vaccines 
prequaliﬁ ed by WHO for procurement 
by UN agencies.4 However, the WHO 
Strategic Advisory Group of Experts 
on Immunization raised concerns 
that overly precautionary language 
in package inserts regarding vaccine 
safety in pregnancy could contribute 
to hesitancy.5 We sought to evaluate 
the effect of the package insert 
language on the perceptions of 
providers of maternal health care on 
vaccine safety and use in pregnant 
women.
We recruited health-care providers 
at two international maternal health 
conferences and from non-vaccine-
related teaching programmes in 
Ethiopia, Ghana, Uganda, and 
Laos from Sept 11 to Oct 31, 2015. 
Individuals who provided health care 
to pregnant women were invited to 
complete a ten-item questionnaire in 
English, French, or Spanish. Following 
verbal consent, the questionnaire was 
provided using a tablet computer via 
an online survey platform. Printed 
questionnaires (in English) were used 
at the teaching programme sites.
We developed the questionnaire to 
capture demographics and perceptions 
of vaccine safety and use by pregnant 
women after respondents read three 
different package insert statements 
for equivalent WHO pre-qualified 
seasonal inactivated influenza 
vaccines. A negatively framed 
statement emphasised uncertainty 
about safety and effectiveness: 
“safety and eﬀ ectiveness in pregnancy 
is not established… [use] only if 
clearly needed” (Fluzone, Sanofi 
Pasteur, Swiftwater, PA, USA). Two 
more positively framed statements 
emphasised conditions for vaccine 
use: positively framed statement A: 
“use only following the advice of a 
healthcare professional, based on 
consideration of the beneﬁ ts and risks 
to the mother and foetus” (FluLaval, 
GlaxoSmithKline, Sainte-Foy, QC, 
Canada), and even more positively 
framed statement B: “use only from 
the second pregnancy trimester 
onwards… [use throughout pregnancy 
in women] at risk of complications of 
infection” (Vaxigrip, Sanofi Pasteur, 
Lyon, France).4 After reading each 
statement, respondents indicated how 
safe they thought the vaccine was on 
a Likert scale (moderately/very safe, 
neutral, moderately/very unsafe, don’t 
know). They were then asked whether 
they would recommend this vaccine 
if it was recommended by national 
health authorities (yes, no, don’t 
know/no response), and whether the 
statements would aﬀ ect what they told 
pregnant women about immunisation 
(yes, no, don’t know/no response).
We used Opinio survey software 
version 6.9.1, which was hosted 
on a computer server in Halifax, 
NS,  Canada.  We used SAS 
version 9.4 (SAS Institute, Cary, NC, 
USA) for the analysis. The IWK Health 
Centre Research Ethics Board and WHO 
Research Ethics Review Committee 
approved the study. 
Figure: Perceptions of negatively and positively framed precautionary statements 
about vaccine use during pregnancy
Positive statement B not assessed in the ﬁ nal question. LMIC=low-income and 
middle-income countries (n=105). HIC=high-income countries (n=36). *p=0·02.
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Regulatory authorities, manu-
facturers, and public health organ-
isations should work towards 
reconciling the perceived disagreement 
between their respective documents 
and developing a language that is 
unambiguous to health-care providers. 
Research is needed to determine the 
optimal package insert content and 
language that is readily understood 
by health-care providers and that 
facilitates appropriate, evidence-based 
use of vaccines. Reproducing national 
or WHO recommendations for vaccine 
use during pregnancy in the package 
insert, when they are aligned with the 
product’s safety proﬁ le, could provide 
health-care workers with specific 
guidance. Such measures might help to 
improve vaccine uptake in pregnancy.
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and 117 (83%) were recruited 
from the conferences. 112 (80%) 
respondents were obstetricians, 
15 (11%) were midwives or nurses, 
and 13 (9%) were other professionals. 
111 (79%) respondents prescribed or 
administered vaccines to pregnant 
women. 106 (75%) respondents read 
vaccine package inserts occasionally, 
often, or for new products. 
Respondents from LMICs were 
significantly more likely than those 
from high-income countries (HICs) to 
read package inserts (80% [84 of 105] 
vs 61% [22 of 36], p=0·02). 
Responses to the package insert 
statements, stratified by country 
income level, are shown in the ﬁ gure. 
After reading the negatively framed 
package insert statement, 46 (44%) 
of respondents from LMICs perceived 
the vaccine described in the statement 
as unsafe and 26 (25%) perceived 
it as safe (figure 1A). After reading 
positively framed statement B, 
31 (30%) of respondents from LMICs 
perceived the vaccine as unsafe and 
56 (53%) perceived it as safe. Most 
respondents from LMICs (83, 79%) 
and HICs (20, 56%) indicated that 
the package insert statements would 
aﬀ ect how they counselled pregnant 
women about immunisation (p=0·02; 
ﬁ gure 1C). Responses to the package 
insert statements did not differ by 
WHO region or profession (data not 
shown). 
The findings suggest that health-
care providers perceive package 
insert information as contradicting 
WHO and national immunisation 
recommendations, and that this 
perceived disagreement could 
aﬀ ect their decisions to recommend 
immunisation to pregnant women. 
Although the study was limited by the 
convenience sampling approach, which 
precluded calculation of the response 
rate and might have introduced 
selection bias, the similarities in 
responses between participants from 
HICs and LMICs suggest that package 
insert language can raise safety 
concerns in many settings. 
